CoChat

Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in LKB1 -Mutant Lung Cancer

Open access
Liu, Yan, Marks, Kevin, Cowley, Glenn S., Carretero, Julian, Liu, Qingsong, Nieland, Thomas J.F., Xu, Chunxiao, Cohoon, Travis J., Gao, Peng, Zhang, Yong, Chen, Zhao, Altabef, Abigail B., Tchaicha, Jeremy H., Wang, Xiaoxu, Choe, Sung, Driggers, Edward M., Zhang, Jianming, Bailey, Sean T., Sharpless, Norman E., Hayes, D. Neil, Patel, Nirali M., Janne, Pasi A., Bardeesy, Nabeel, Engelman, Jeffrey A., Manning, Brendan D., Shaw, Reuben J., Asara, John M., Scully, Ralph, Kimmelman, Alec, Byers, Lauren A., Gibbons, Don L., Wistuba, Ignacio I., Heymach, John V., Kwiatkowski, David J., Kim, William Y., Kung, Andrew L., Gray, Nathanael S., Root, David E., Cantley, Lewis C., Wong, Kwok-Kin · 2013 · Cancer Discovery
Cited by 157

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

The LKB1/STK11 tumor suppressor encodes a serine/threonine kinase, which coordinates cell growth, polarity, motility, and metabolism. In non–small cell lung carcinoma, LKB1 is somatically inactivated in 25% to 30% of cases, often concurrently with activating KRAS mutations. Here, we used an integrative approach to define novel therapeutic targets in KRAS-driven LKB1-mutant lung cancers. High-throughput RNA interference screens in lung cancer cell lines from genetically engineered mouse models driven by activated KRAS with or without coincident Lkb1 deletion led to the identification of Dtymk, encoding deoxythymidylate kinase (DTYMK), which catalyzes dTTP biosynthesis, as synthetically lethal with Lkb1 deficiency in mouse and human lung cancer lines. Global metabolite profiling showed that Lkb1-null cells had a striking decrease in multiple nucleotide metabolites as compared with the Lkb1–wild-type cells. Thus, LKB1-mutant lung cancers have deficits in nucleotide metabolism that confer hypersensitivity to DTYMK inhibition, suggesting that DTYMK is a potential therapeutic target in this aggressive subset of tumors. Significance: Using cell lines derived from the lung cancers occurring in genetically engineered mice, we conducted an integrative genome-wide short hairpin RNA and metabolite screen to identify DTYMK as a potential therapeutic target in Kras/Lkb1–mutant lung cancer. We believe that DTYMK is tractable for the development of novel therapeutics, and show an integrative approach to target identification that reduces false-positive candidates and should have broad applicability for the development of targeted therapeutics. Cancer Discov; 3(8); 870–9. ©2013 AACR. See related commentary by Marcus and Khuri, p. 843 This article is highlighted in the In This Issue feature, p. 826

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-13-0015

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 157

Metadata

Authors
Liu, Y., Marks, K., Cowley, G. S., Carretero, J., Liu, Q., Nieland, T. J. F., Xu, C., Cohoon, T. J., Gao, P., Zhang, Y., Chen, Z., Altabef, A. B., Tchaicha, J. H., Wang, X., Choe, S., Driggers, E. M., Zhang, J., Bailey, S. T., Sharpless, N. E., Hayes, D. N., Patel, N. M., Janne, P. A., Bardeesy, N., Engelman, J. A., Manning, B. D., Shaw, R. J., Asara, J. M., Scully, R., Kimmelman, A., Byers, L. A., Gibbons, D. L., Wistuba, I. I., Heymach, J. V., Kwiatkowski, D. J., Kim, W. Y., Kung, A. L., Gray, N. S., Root, D. E., Cantley, L. C., & Wong, K.-K.
Venue
Cancer Discovery
Published
2013-08-01
Volume
3
Issue
8
Pages
870-879
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2116716449
Cited by
157
References
7
FWCI
9.50
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.